Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Our multiomic analysis uncovered mechanisms of tumor response to immunotherapy combined with dual HER2 blockade. These results could inform the design of larger trials investigating chemotherapy-free regimens in selected patients with HER2+ early breast cancer.
Authors
- Daniel Ulbrich-Gebauer (ORCID: https://orcid.org/0000-0001-5793-4873)
- Katarzyna Jóźwiak (ORCID: https://orcid.org/0000-0002-9614-6586)
- Ulrike Nitz (ORCID: https://orcid.org/0000-0003-0143-0507)
- Oleg Gluz (ORCID: https://orcid.org/0000-0001-6019-7544)
- Matthias Christgen (ORCID: https://orcid.org/0000-0002-0891-7839)
- Felix Hilpert (ORCID: https://orcid.org/0000-0002-3492-9577)
- Jens‐Uwe Blohmer (ORCID: https://orcid.org/0000-0002-7969-250X)
- Nadia Harbeck (ORCID: https://orcid.org/0000-0002-9744-7372)
- Andreas D. Hartkopf (ORCID: https://orcid.org/0000-0003-1227-1118)
- Monika Graeser (ORCID: https://orcid.org/0000-0003-1916-717X)
- Christine zu Eulenburg (ORCID: https://orcid.org/0000-0001-9365-5548)
- Claudia Biehl (ORCID: https://orcid.org/0000-0002-7736-289X)
- Hans Heinrich Kreipe (ORCID: https://orcid.org/0000-0003-0708-1790)
- Michael Braun (ORCID: https://orcid.org/0000-0002-6666-4868)
- Mattea Reinisch (ORCID: https://orcid.org/0000-0002-1381-8595)
- Friedrich Feuerhake (ORCID: https://orcid.org/0000-0002-1234-982X)
- Peter Schmid (ORCID: https://orcid.org/0000-0001-9817-5228)
- Kerstin Lüdtke-Heckenkamp (ORCID: https://orcid.org/0000-0003-3153-6871)
- Valery Volk (ORCID: https://orcid.org/0000-0002-8928-4470)
- Sherko Kuemmel (ORCID: https://orcid.org/0000-0001-9355-494X)
- Enrico Pelz (ORCID: https://orcid.org/0000-0002-8605-2172)
Institutions
- Witten/Herdecke University (DE)
- Universität Hamburg (DE)
- University of Freiburg (DE)
- Queen Mary University of London (GB)
- University of Mannheim (DE)
- University of Cologne (DE)
- Heidelberg University (DE)
- University Medical Center Freiburg (DE)
- Deutsches Archäologisches Institut, Zentrale (DE)
- University Hospital Heidelberg (DE)
- Medizinische Hochschule Hannover (DE)
- MSH Medical School Hamburg – University of Applied Sciences and Medical University (DE)
- Krankenhaus vom Roten Kreuz (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Hochschule Niederrhein (DE)
- München Klinik (DE)
- Asklepios Klinik St. Georg (DE)
- Klinik Niederrhein (DE)
- University Children's Hospital Tübingen (DE)
- Klinikum Dortmund (DE)
- Medizinische Hochschule Brandenburg Theodor Fontane (DE)
- Kliniken Essen-Mitte (DE)
- Rotkreuzklinikum München (DE)
- LVR-Klinik für Orthopädie Viersen (DE)
- Städtische Kliniken Mönchengladbach (DE)
- Marienhospital Osnabrück (DE)
- University Hospital Cologne (DE)
- University Medical Centre Mannheim (DE)
- Krankenhaus Jerusalem (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1923
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00